SGMT

Sagimet is a pre-revenue, clinical-stage biopharma whose entire value rests on one molecule: denifanstat, an oral FASN inhibitor for MASH (plus acne and cancer). The fundamentals are exactly what you'd expect for a story stock — there is essentially no product revenue (the only figure on file is $2.0M back in FY2023), and losses are widening: FY2025 net loss of -$51.0M (a fourth straight year of deepening red after -$30.5M, -$27.9M, -$45.6M), operating margin of -2,844% and a -$346M accumulated deficit. Conventional multiples are meaningless here — the 123x P/S and -45.8% ROE describe an R&D burn engine, not a business. This is an option on a binary clinical outcome, and it must be sized as one.

What keeps this at hold rather than avoid is that the balance sheet is clean and the lead asset is genuinely de-risked. Liabilities are trivial versus equity (0.05x), and while cash & equivalents fell 54% to $35.0M, current assets of $116M dwarf $5.1M of current liabilities — implying a sizeable marketable-securities buffer beyond headline cash. Against a ~$45.6M annual operating cash burn that points to roughly two years of runway, not an imminent going-concern cliff. More importantly, the MD&A reports that denifanstat met all primary and multiple secondary endpoints in the 168-patient Phase 2b FASCINATE-2 trial, with 1-stage fibrosis improvement of 49% vs 13% placebo (p=0.0032) in the F3 population, a statistically significant reduction in progression to cirrhosis, and a benefit even on top of GLP-1 background therapy — published in The Lancet Gastro. The December 2025 completion of a clean Phase 1 PK combo study with Rezdiffra (resmetirom) opens a differentiated F4-cirrhosis path. For a $246M market cap, that is a modest price on positive Phase 2b data in a very large MASH market.